EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|September 1, 2003
Clear Those Warts
Author(s)Alison Palkhivala
San Francisco - Not only are warts a cosmetic nuisance, they may also cause considerable discomfort and even be linked to higher cancer rates. Clearing warts, therefore, is an important consideration for dermatologists. Nanette Silverberg, M.D., director, pediatric dermatology, department of dermatology, St. Luke's-Roosevelt and Beth Israel Medical Centers, New York City, provided some tips on how best to do that.
Advertisement
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Alopecia Areata Awareness Month: 2026 in Review
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
5